Recent Updates

Modified on: 
Jan 22, 2019

Background

Originally all plasma fractionation products were derived from pooled human plasma. Increasingly, many plasma proteins are manufactured by biotechnology as recombinant proteins, without need of donated plasma; depending on the particular plasma protein product, a recombinant or a fractionated product or both are available in Canada.

This Chapter presents in general terms the various methods and principles by which plasma protein products are manufactured for use in patients. It is complemented by Chapter 3, 4, 5 and 6 of this Guide.

Transfusion
Modified on: 
Jan 22, 2019

A. Reporting

Attention: All transfusion reactions (mild to life-threatening) and transfusion-related errors must be reported to the hospital’s transfusion service (blood bank).

Transfusion
Modified on: 
Jan 22, 2019

This chapter describes the manufacturing process for the most commonly prepared blood products: Red Blood Cells, Pooled Platelets, Frozen Plasma (FP), Apheresis Fresh Frozen Plasma (AFFP), Cryosupernatant Plasma (CSP) and Cryoprecipitate. A brief description of the indications, contraindications, storage and transportation requirements, dose, administration and available alternatives is included in the sections below. Further information may be found in other chapters of this Guide as indicated within the different sections.

Transfusion
Modified on: 
Jan 22, 2019

This first chapter of the Clinical Guide to Transfusion provides an overview of the blood system in Canada, the regulations and standards that are in place and the organizations and professionals that, together, ensure transfusion medicine safety for Canadian patients. 

Transfusion
Modified on: 
Jan 21, 2019

Report and Recommendations (July 2005)

PDF


Organs and Tissues
Modified on: 
Jan 17, 2019

“Paying it Forward: Why we need YOU to give blood" is an article by Dr. Jeannie Callum, a hospital-based transfusion specialist. Here she shares her real-life experience witnessing the impact of blood donation on patient lives. She provides some fascinating insight into blood transfusion, past and present, and emphasizes the need for male donors and why some donors may be safer for patients. This article is also being published in six parts on RED, our Research, Education and Discovery blog.  

Transfusion
Modified on: 
Jan 17, 2019

In August 2017, Canadian Blood Services changed its platelet product testing procedure to improve the detection of bacterial contamination. This change enhanced the safety of Canadian Blood Services platelet products and provided the opportunity to improve inventory management by extending the platelet shelf life from five to seven days.

Transfusion
Modified on: 
Jan 17, 2019

Immune globulin (Ig) products are generated from plasma collected from a large number of carefully screened donors. Ig products may be used as replacement therapy for immunodeficiency patients or as immunomodulatory therapy for autoimmune and alloimmune disorders. Ig products include intravenous Ig (IVIg), subcutaneous Ig (SCIg), RhD Ig (RhIg) and hyperimmune globulins.

Transfusion
Modified on: 
Jan 16, 2019

Increasing tissue donation in deaths occurring out of hospital

Welcome to the Canadian Blood Services continuing education registration page

Our OnPoint education portal now offers the following course: Increasing Tissue Donation in Deaths Occurring Out of Hospital

Organs and Tissues
Modified on: 
Jan 16, 2019

A very small percentage of red blood cell units are manufactured from blood donors with red cell antibodies. These donors may have antibodies directed against common non-ABO antigens detected during routine screening or may represent a rare blood donor with the corresponding antibody. 

Transfusion

Pages